Time to watch: How Timber Pharmaceuticals (TMBR) shares jumped in the AH session

Timber Pharmaceuticals (NYSE: TMBR) rose 23.97% to $1.5 in the after-market session. This stock has wildly shifted this year, with buyers keen to raise stock rates for simple business news or no news at all.

Nevertheless, on December 10, 2020, A biopharmaceutical corporation focusing on the production and commercialization of therapies for rare and orphan dermatological disorders revealed that it would host a corporate update conference call for analysts and shareholders.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Timber’s Chief Executive Officer, John Koconis, and Chief Financial Officer, Joe Lucchese, will host the call.

Conference Call Information

It will be held on Thursday, December 17th, at 11:00 am EST. 

To join the call: Contact (877) 270-2148 and ask to be joined into the Timber Pharmaceuticals call. 

There will also be a live webcast of the conference call, which can be accessed at: 

https://services.choruscall.com/links/timberpharma201217.html For those unable to 

participate in the live conference call; a replay will be archived and available on 

Timber’s website under the Investor Relations tab at www.timberpharma.com.

Most Popular

Related posts